VX-710
VX-710 (also known as Biricodar) is a multi-drug resistance inhibitor that was developed by Vertex Pharmaceuticals. It was designed to enhance the effectiveness of chemotherapy drugs by preventing the cancer cells from pumping out the drugs before they can have an effect.
History[edit | edit source]
VX-710 was first developed in the late 1990s by Vertex Pharmaceuticals, a biotechnology company based in Cambridge, Massachusetts. The drug was part of a new class of drugs known as multi-drug resistance inhibitors, which were designed to overcome one of the major obstacles in cancer treatment: the ability of cancer cells to become resistant to chemotherapy drugs.
Mechanism of Action[edit | edit source]
VX-710 works by inhibiting the action of a protein known as P-glycoprotein, which is often overexpressed in cancer cells and is responsible for pumping out chemotherapy drugs, thereby rendering them ineffective. By inhibiting P-glycoprotein, VX-710 allows the chemotherapy drugs to remain inside the cancer cells longer, increasing their effectiveness.
Clinical Trials[edit | edit source]
Several clinical trials were conducted to test the effectiveness of VX-710. In a Phase II trial, VX-710 was combined with the chemotherapy drugs doxorubicin and vincristine in patients with advanced, drug-resistant cancers. The results showed that the combination of VX-710 with these drugs was safe and had some activity against the cancer.
However, in a subsequent Phase III trial, VX-710 failed to show a significant improvement in survival in patients with drug-resistant ovarian cancer. This led to the discontinuation of the development of VX-710 as a standalone drug.
Current Status[edit | edit source]
Despite the initial promise of VX-710, the drug is no longer being developed by Vertex Pharmaceuticals. However, the concept of multi-drug resistance inhibitors remains an active area of research in the field of oncology, with several other drugs being developed to target P-glycoprotein and other mechanisms of drug resistance.
See Also[edit | edit source]
This pharmaceutical related article is a stub. You can help WikiMD by expanding it.
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
